Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in PharmExec, in “Pharma Raises Stakes in Digital Health,” by Michelle Maskaly.
Following is an excerpt:
“There are so many issues that selling pills by themselves can’t solve because other factors are involved,” says Bradley Merrill Thompson, a partner at national healthcare law firm Epstein Becker Green. “The lack of patients taking medicine is a prime example. If pharma companies just make pills, they are going to hit a wall trying to change patient behavior.” …
“Pharma companies want to get into the outcomes business,” Thompson told Pharm Exec. “They want to help make people healthier.”
